Announced Wed, 7 Oct, 2026 · 22:43 IST
Tavexia Lifecare to acquire 60% in Meyonex Pharma for Rs 67.19 cr
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
—1-day move
₹1.20
prior close
₹1.25
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.0-3.2-3.2-3.2——————————
Up moveDown movePending
AI summary
Tavexia Lifecare board approved acquiring 60% stake in unlisted Meyonex Pharmaceuticals by subscribing to about 2.10 crore fresh shares at Rs 32 each, totaling Rs 67.19 crore in cash. Meyonex is a pharma company with FY25 turnover of about Rs 108 crore. Board also approved in principle raising funds via equity, warrants or debt on preferential or rights basis to finance the deal. Transaction is subject to shareholder and regulatory approvals.
Likely market impact
Major expansion into pharma via controlling acquisition. Funding route yet to be finalised, so watch for potential equity dilution and shareholder vote outcome.